FDA staff is against approving Bystolic for heart failure

01/7/2010 | Reuters

FDA reviewers warned that a study on using Forest Laboratories' blood pressure drug Bystolic in heart failure patients underwent "several critical changes" that could have skewed the results. "The totality of evidence is not convincing to support a claim for treatment of heart failure" with Bystolic, said FDA staff, which issued the opinion ahead of a panel evaluation Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN